87(7):732-3.Ĭassinerio E, Roghi A, Pedrotti P, Brevi F, Zanaboni L, Graziadei G, et al. Long-term improvement in cardiac magnetic resonance in β-thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function. 95 (14):e3150.Ĭasale M, Filosa A, Ragozzino A, Amendola G, Roberti D, Tartaglione I, et al. ![]() Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review. Hepcidin and iron regulation, 10 years later. Does erythropoietin have a role in the treatment of ß-hemoglobinopathies?. Maria-Domenica C, 55th Annual ASH Meeting abstracts, 2013, abstract # 3448.įibach E, Rachmilewitz EA. Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. 28(2):233-48.ĭulmovits BM, Appiah-Kubi AO, Papoin J, Hale J, He M, Al-Abed Y, et al. Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies. Raechel P et al, 55th Annual ASH Meeting abstracts, 2013, abstract # 1022. Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India. β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies. Presented at the American Society of Pediatric Hematology/Oncology (ASPHO) 2022 May 3-6. Betibeglogene autotemcel in pediatric patients with transfusion-dependent beta-thalassemia in phase 3 trials (Plenary Paper #2002). Betibeglogene Autotemcel Gene Therapy for Non-β 0/β 0 Genotype β-Thalassemia. Locatelli F, Thompson AA, Kwiatkowski JL, Porter JB, Thrasher AJ, Hongeng S, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. 11:9-28.įrangoul H, Altshuler D, Cappellini MD, et al. Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-Thalassemia. ![]() Lidonnici MR, Paleari Y, Tiboni F, Mandelli G, Rossi C, Vezzoli M, et al. Gene Therapy Approaches to Hemoglobinopathies. 2015 May 28.įerrari G, Cavazzana M, Mavilio F. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload. 329(12):840-4.Įlalfy MS, Saber MM, Adly AA, Ismail EA, Tarif M, Ibrahim F, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. Thomas ED, Buckner CD, Sanders JE, Papayannopoulou T, Borgna-Pignatti C, De Stefano P. Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy. Erythropoiesis is not equally suppressed in transfused males and females with β-thalassemia major: are there clinical implications?. Hapgood G, Walsh T, Cukierman R, Paul E, Cheng K, Bowden DK. The role of hemoglobin heme loss in Heinz body formation: studies with a partially heme-deficient hemoglobin and with genetically unstable hemoglobins. Cardiovascular function and treatment in ß-thalassemia major: a consensus statement from the American Heart Association. Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R. Hair-on-end appearance in radiograph of skull and facial bones in a case of beta thalassaemia. Screening for thalassemia carriers in populations with a high rate of iron deficiency: revisiting the applicability of the Mentzer Index and the effect of iron deficiency on Hb A2 levels. 2018 Dec 10.Īmid A, Haghi-Ashtiani B, Kirby-Allen M, Haghi-Ashtiani MT. Atrial fibrillation in β-thalassemia patients with a focus on the role of iron-overload and oxidative stress: A review. Nomani H, Bayat G, Sahebkar A, Fazelifar AF, Vakilian F, Jomezade V, et al. Thalassemia review: features, dental considerations and management. Neurological complications of beta-thalassemia. ![]() Nemtsas P, Arnaoutoglou M, Perifanis V, Koutsouraki E, Orologas A. Amelioration of Sardinian beta0 thalassemia by genetic modifiers. Galanello R, Sanna S, Perseu L, Sollaino MC, Satta S, Lai ME, et al. Diagnosis and treatment of cardiac iron overload in transfusion-dependent thalassemia patients. ![]() Siri-Angkul N, Chattipakorn SC, Chattipakorn N.
0 Comments
Leave a Reply. |